Literature DB >> 12110640

Concurrent mutations of K-ras oncogene at codons 12 and 22 in colon cancer.

Yasuyuki Miyakura1, Kokichi Sugano, Noriko Fukayama, Fumio Konishi, Hideo Nagai.   

Abstract

K-ras mutation is the most common oncogenic alteration in various human cancers including colorectal carcinomas. Point mutations have the potential to activate the K-ras gene if they occur in the critical coding sequences. Almost all of these mutations have been localized in codons 12, 13 and 61. We report a case of colon cancer presenting point mutations at both codons 12 and 22 of the K-ras gene. PCR-SSCP and subsequent sequencing revealed that GGT (glycine, wild-type) to AGT (serine) substitution at codon 12 and CAG (glutamine, wild-type) to CGG (arginine) substitution at codon 22 occurred in the same allele.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12110640     DOI: 10.1093/jjco/hyf043

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  6 in total

1.  Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations.

Authors:  Martin Zenker; Katarina Lehmann; Anna Leana Schulz; Helmut Barth; Dagmar Hansmann; Rainer Koenig; Rudolf Korinthenberg; Martina Kreiss-Nachtsheim; Peter Meinecke; Susanne Morlot; Stefan Mundlos; Anne S Quante; Salmo Raskin; Dirk Schnabel; Lars-Erik Wehner; Christian P Kratz; Denise Horn; Kerstin Kutsche
Journal:  J Med Genet       Date:  2006-10-20       Impact factor: 6.318

2.  Activation of K-RAS by co-mutation of codons 19 and 20 is transforming.

Authors:  Adam Naguib; Catherine H Wilson; David J Adams; Mark J Arends
Journal:  J Mol Signal       Date:  2011-03-03

3.  Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine.

Authors:  G Smith; R Bounds; H Wolf; R J C Steele; F A Carey; C R Wolf
Journal:  Br J Cancer       Date:  2010-02-16       Impact factor: 7.640

Review 4.  Mechanistic regulation of epithelial-to-mesenchymal transition through RAS signaling pathway and therapeutic implications in human cancer.

Authors:  Kiran Tripathi; Minal Garg
Journal:  J Cell Commun Signal       Date:  2018-01-12       Impact factor: 5.782

5.  Analysis of mutations in TP53, APC, K-ras, and DCC genes in the non-dysplastic mucosa of patients with inflammatory bowel disease.

Authors:  Davy Carlos Mendes Rapozo; Ana Braunstein Grinmann; Ana Teresa Pugas Carvalho; Heitor Siffert P de Souza; Sheila Coelho Soares-Lima; Tatiana de Almeida Simão; Daurita de Paiva; Flávio Abby; Rodolpho Mattos Albano; Luiz Felipe Ribeiro Pinto
Journal:  Int J Colorectal Dis       Date:  2009-06-20       Impact factor: 2.571

6.  Experiences from treatment-predictive KRAS testing; high mutation frequency in rectal cancers from females and concurrent mutations in the same tumor.

Authors:  Mats Jönsson; Anna Ekstrand; Thomas Edekling; Jakob Eberhard; Dorthe Grabau; David Borg; Mef Nilbert
Journal:  BMC Clin Pathol       Date:  2009-10-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.